Rankings
▼
Calendar
▼
LBRX Q3 2024 Earnings Report — LB Pharmaceuticals Inc Common Stock Revenue & Financial Results | Market Cap Arena
LB Pharmaceuticals Inc Common Stock
LBRX
Q3 2024 Earnings
Reported September 29, 2024
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Free Cash Flow
Metric
Q3 2024
Q2 2024
Q3 2023
QoQ Change
YoY Change
Revenue
$0
$0
—
—
—
Op. Income
-$16M
-$27M
—
39.5%
—
EPS (Diluted)
$-0.63
$-7.82
—
91.9%
—
Free Cash Flow
-$22M
-$16M
—
-42.1%
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$5.0K
GROSS PROFIT
-$5.0K
R&D Expenses
$11M
Selling & Marketing
$0
General & Administrative
$0
SG&A Expenses
$5M
Other Expenses
$0
Operating Expenses
$16M
Cost & Expenses
$16M
OPERATING INCOME
-$16M
Interest Income
$384.0K
Interest Expense
$0
Other Income/Expenses
$2M
INCOME BEFORE TAX
-$14M
Income Tax Expense
$0
Net Income from Continuing Ops
-$14M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$14M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$14M
D&A
$5.0K
EBIT
-$14M
EBITDA
-$14M
EPS
-$1
EPS Diluted
-$1
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$14M
Depreciation & Amortization
$5.0K
Stock-Based Compensation
$472.0K
Deferred Income Tax
$0
Other Non-Cash Items
$2M
Change in Working Capital
-$10M
OPERATING CASH FLOW
-$22M
Capital Expenditure
-$443.0K
Acquisitions (Net)
$0
Purchases of Investments
$0
Sales/Maturities of Investments
$29M
Other Investing Activities
$0
NET CASH FROM INVESTING
$29M
Net Debt Issuance
$0
Common Stock Repurchased
$0
Common Dividends Paid
$0
Other Financing Activities
$0
NET CASH FROM FINANCING
$20.0K
FREE CASH FLOW
-$22M
Net Change in Cash
$0
marketcaparena.com
← FY 2024
LBRX Overview
Q1 2025 →